investigator_user investigator user funding collaborators pending menu bell message arrow_up arrow_down filter layers globe marker add arrow close download edit facebook info linkedin minus plus save share search sort twitter remove user-plus user-minus
  • Project leads
  • Collaborators

Sphingosine-1-Phosphate in Breast Cancer Progression and Lymphangiogenesis

Kazuaki Takabe

0 Collaborator(s)

Funding source

National Cancer Institute (NIH)
Approximately 40,000 women die from breast cancer every year. The extent of lymph node metastasis is a major determinant for staging and prognosis of this disease. Clinical and experimental evidence suggests that migration of cancer cells into lymph nodes is also mediated by lymphangiogenesis, a process that generates new lymphatic vessels from pre-existing ones. Nevertheless, the molecular mechanisms of tumor-induced lymphangiogenesis are not well understood. Sphingosine-1-phosphate (S1P), a bioactive lipid mediator and a ligand for specific S1P receptors regulates critical processes of breast cancer progression, such as cell proliferation, migration and angiogenesis. Sphingosine kinase 1 (SphK1), the enzyme that generates S1P, is up-regulated in breast cancer and is associated with resistance to chemotherapy and correlates with a poor prognosis. We have recently shown that ATP-binding cassette transporters export S1P from breast cancer cells, and subsequently activate its receptors by "inside-out signaling". Our preliminary studies suggest that S1P also plays an important role in tumor-induced lymphangiogenesis. We have found that S1P induces lymphangiogenesis via the S1PR1 receptor on lymphatic endothelial cells (LECs) and it stimulates these cells to release angiopoietin 2 (Ang2), a critical regulator of lymphangiogenesis, whose levels in breast cancer correlate with metastases to lymph nodes and poor prognosis. The goal of this proposal is to determine the role of SphK1/S1P/S1PR1 axis and its crosstalk with Ang2 pathway to form a feed-forward amplification loop and explore its possibility as a target for treatment. We will examine the hypothesis that S1P produced by SphK1 is a previously uncharacterized cancer-induced lymphangiogenic factor that is critical for breast cancer progression and metastasis. Pharmacological, molecular biological and extensive genetic approaches will be utilized to determine the intricate crosstalk between S1P, released from the primary tumor and/or LECs, and Ang2, released from LECs via the S1PR1 receptor to form a feed-forward amplification loop, and evaluate their important roles in breast cancer-induced lymphangiogenesis. We will further elucidate their impact in lymph node metastasis and reduced survival utilizing our validated syngeneic breast cancer metastasis model, and explore clinical evidence using patient samples to support our hypothesis. Collectively, these studies will lead to better understanding of the role of SphK1/S1P/S1P1 axis in lymphangiogenesis and breast cancer biology that could lay the foundation for the addition of a novel S1P-targeted modality of treatment to the armamentarium of anti-breast cancer agents.

Related projects